<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765008</url>
  </required_header>
  <id_info>
    <org_study_id>FP00018531</org_study_id>
    <nct_id>NCT03765008</nct_id>
  </id_info>
  <brief_title>The Effect of Water Intake on Glucose Regulation</brief_title>
  <acronym>INDIGO-I</acronym>
  <official_title>The Effect of Water Intake on Glucose Regulation: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arizona State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a growing body of evidence suggesting low water intake and elevated levels of the
      hormone vasopressin exacerbate glucose regulation. This project will examine the
      physiological mechanism by which low water intake impairs glucose homeostasis.

      In the current proposal we aim to: 1) quantify the degree of glucose impairment as a response
      to elevated vasopressin due to low water intake and 2) identify the physiological mechanism
      by which elevated vasopressin, as a response to low water intake, impairs glucose regulation
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study did not get funded
  </why_stopped>
  <start_date type="Anticipated">February 11, 2019</start_date>
  <completion_date type="Anticipated">April 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount of glucose metabolized M</measure>
    <time_frame>220-240 min &amp; 340-360 min of the protocol</time_frame>
    <description>amount of glucose metabolized during the euglycemic &amp; Hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolic clearance rate for insulin</measure>
    <time_frame>220-240 min &amp; 340-360 min of the protocol</time_frame>
    <description>metabolic clearance rate for insulin during the euglycemic &amp; Hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>quantity of glucose metabolized per unit plasma insulin concentration</measure>
    <time_frame>220-240 min &amp; 340-360 min of the protocol</time_frame>
    <description>quantity of glucose metabolized per unit plasma insulin concentration during the euglycemic &amp; Hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of glucose appearance &amp; disappearance</measure>
    <time_frame>220-240 min &amp; 340-360 min of the protocol</time_frame>
    <description>Rate of glucose appearance &amp; disappearance during the euglycemic &amp; Hyperglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma copeptin</measure>
    <time_frame>0 min, 240 min &amp; 360 min of the protocol</time_frame>
    <description>Plasma copeptin in response to water manipulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon</measure>
    <time_frame>0 min, 240 min &amp; 360 min of the protocol</time_frame>
    <description>glucagon in response to water manipulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol</measure>
    <time_frame>0 min, 240 min &amp; 360 min of the protocol</time_frame>
    <description>Cortisol in response to water manipulation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Dehydration (Physiology)</condition>
  <condition>Water Deprivation</condition>
  <arm_group>
    <arm_group_label>High Water intake</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-days of High water intake according to IOM guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Water Intake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-days of Low water intake of 500 mL/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water intake manipulation</intervention_name>
    <description>for 5 days prior to each experiment subjects will undergo manipulation of their water intake.</description>
    <arm_group_label>High Water intake</arm_group_label>
    <arm_group_label>Low Water Intake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        BMI 27.5-35

        Exclusion Criteria:

          -  BMI &lt;27.5 or &gt;35

          -  high physical activity

          -  diabetes

          -  impaired liver or kidney function

          -  cardiovascular disease

          -  weight change of more than 3 kg in the past month

          -  pregnancy

          -  previous surgery on digestive tract (except appendectomy)

          -  fluid balance will be exclusionary such as

          -  serotonin re-uptake inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arizona State University</investigator_affiliation>
    <investigator_full_name>Stavros Kavouras</investigator_full_name>
    <investigator_title>Professor of Nutrition</investigator_title>
  </responsible_party>
  <keyword>water</keyword>
  <keyword>vasopressin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

